TRDA

4.3506.25%
NS

Natarajan Sethuraman

President of Research & Development

Dr. Natarajan Sethuraman, Ph.D., has been President of Research and Development of Entrada Therapeutics, Inc. since 2024 and also served as Chief Scientific Officer September 2017 until 2024 and previously served as a consultant from October 2016 to August 2017. He joined Entrada as Chief Scientific Officer in 2017. Dr. Sethuraman was Executive Director and the GlycoFi Site Head at Merck. Dr. Sethuraman was also part of the Biologics Discovery leadership team at Merck Research Laboratories which set the strategy and prioritization of all Merck biologics. Dr. Sethuraman joined Merck through its acquisition of GlycoFi in 2006. At GlycoFi, Dr. Sethuraman was responsible for all downstream process development and preclinical studies as well as serving as the key scientific liaison for many of GlycoFi’s collaborations. Dr. Sethuraman holds a BSc from Tamil Nadu Agricultural University from 1979 to 1983, an M.Sc. in Entomology and Biochemistry from the Indian Agricultural Research Institute and a PhD in Entomology, Molecular Biology and Biochemistry from the Indian Agricultural Research Institute from 1983 to 1988. He received his post-doctoral training at Duke University where he worked on the elucidation of the termination of DNA replication in E. coli.

Positions